NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that no further patients will be enrolled in its dose escalating Phase I study (NZ-DTX-001) with the primary objective to study safety of NanoZolid®-docetaxel in solid tumors. The data collected in the trial demonstrates safety and tolerability, an active and local drug release of docetaxel over an extended period of time and signs of clinical effect in injected tumors.LIDDS plan to communicate the topline results from the study in Q4 2021.
“We have reached an important milestone with the final enrollment of patients in the NZ-DTX-001 study. Preliminary assessments and observations indicate good safety and tolerability in patients treated intratumorally with NanoZolid®-docetaxel. After proper closing of the study, we intend to communicate next step forward for the program” said Nina Herne, CEO of LIDDS.
The clinical Phase I trial NZ-DTX-001 aims to examine whether NanoZolid® in combination with docetaxel, one of the most commonly used drugs for cytostatic treatment of breast, prostate, head, neck, stomach and lung cancer, is safe and tolerable. A secondary objective is to assess efficacy on tumor response.
About the NZ-DTX-001 Phase I study
NZ-DTX-001 is a Phase Ia/Ib, first-in-human, open label, multicenter, dose-escalation and dose-expansion study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX) given as an intratumoral injection in patients with advanced solid tumors. The NZ-DTX-001 study is a multi-center study including Karolinska University Hospital in Sweden, Herlev Hospital in Denmark, Kaunas University Hospital and Vilnius National Cancer Institute in Lithuania.
For more information, please contact:
Nina Herne, CEO, +46 (0)70 714 7457, e-mail: nina.herne@liddspharma.com
LIDDS is required to disclose the information pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act (2007:258). The information was submitted for publication, through the agency of the aforementioned contact, on 4 October 2021 at 19.30 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company focusing on a unique proprietary drug delivery technology: NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North Growth Market (ticker LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: certifiedadviser@redeye.se) For more information, please visit www.liddspharma.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)22.10.2021 20:30:00 CEST | Press release
Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a monthBy continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per yearNeovascular AMD impacts approximately 20 million people worldwide and is a leading cause of blindness in people over the age of 60 Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment wi
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS22.10.2021 16:20:00 CEST | Press release
Anbudsförfarande kommuner och regioner, 2021-10-26BondsFixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2024 The following issuers are accepted for delivery: GÖTEBORGS KOMMUN HELSINGBORGS KOMMUN JÖNKÖPINGS KOMMUN Linköpings Stadshus AB MALMÖ KOMMUN SKÅNE LÄNS LANDSTING STOCKHOLMS KOMMUN STOCKHOLMS LÄNS LANDSTING SÖDERTÄLJE KOMMUN Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2021-10-15BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2021-10-26Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 750 +/- 750 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 750 million. No bid may
CONDITIONS FOR PURCHASES OF CORPORATE BONDS22.10.2021 16:20:00 CEST | Press release
Bid procedure, 2021-10-27BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: HEIMSTADEN BOSTAD AB: XS2259781230, 2025-02-25 CASTELLUM AB: SE0012675916, 2025-11-27 CASTELLUM AB: SE0011062827, 2023-05-17 ESSITY AB: XS2355204608, 2025-01-17 LUNDBERGFORETAGEN AB: SE0012676609, 2025-11-13 LUNDBERGFORETAGEN AB: SE0012676666, 2024-12-06 SVENSK FASTIGHETS FIN: SE0013882719, 2022-11-16 SVENSK FASTIGHETS FIN: SE0012676880, 2022-09-07 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-09-27Bid date2021-10-27Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS2259781230: 30 mln SEK +/-30 mln SEK SE0012675916: 30 mln SEK +/-30 mln SEK SE0011062827: 30 mln SEK +/-30 mln SEK XS2355204608: 30 mln SEK +/-30 mln SEK SE00
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS22.10.2021 16:20:00 CEST | Press release
Bid procedure, 2021-10-28BondsSWEDBANK HYPOTEK AB: 195. SE0013546066. 2025-06-18 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 518, SE0011309244, 2025-09-17 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 Bid date2021-10-28Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)195: 500 mln SEK +/-250 mln SEK 1591: 1700 mln SEK +/-850 mln SEK 146: 800 mln SEK +/-400 mln SEK 580: 500 mln SEK +/-250 mln SEK 518: 500 mln SEK +/-250 mln SEK 2312: 400 mln SEK +/-200 mln SEK 5535: 600 mln SEK +/-300 mln SEK Highest permitted bid volume (corresponding nominal amount)195: 500 mln SEK per bid 1591: 1700 mln SEK per bid 146: 800 mln SEK per bid 580: 500 mln SEK per bid 518: 500 mln SEK per bid 2312: 400 mln SEK per bid 5535: 600 mln SEK per bid Lowest permitted bid volume (co
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS22.10.2021 16:20:00 CEST | Press release
Bid procedure, 2021-10-29BondsSWEDISH GOVERNMENT: 1056. SE0004517290. 2032-06-01 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2021-10-29Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1056: 500 mln SEK +/-250 mln SEK 1053: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1056: 500 mln SEK per bid 1053: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-11-02Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-10-22 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c
Stockwik tillträder Sundisol22.10.2021 16:00:00 CEST | Pressemelding
Stockwik Förvaltning AB (publ) har per idag den 22 oktober 2021 tillträtt Sundisol Aktiebolag och den fastighet från vilken Sundisols verksamhet bedrivs. Samtliga aktier i Sundisol och fastighetsbolaget har förvärvats. Tillträdet är i enlighet med det avtal om förvärv som ingicks och offentliggjordes den 20 oktober 2021. Sundisol är ett bolag med inriktning på installation av akustikplattor och undertak. Sundisol är beläget i Sundsvall och omfattar 11 anställda. Verksamheten har bedrivits sedan 1973. Sundisols omsättning och EBITDA-resultat uppgick för den senaste tolvmånadersperioden per 30 september 2021 till drygt 23,4 MSEK respektive 3,8. Fastighetsbolagets hyresintäkter och EBITDA-resultat uppgick för den senaste tolvmånadersperioden per 30 september 2021 till 0,7 MSEK respektive 0,6. Köpeskillingen för Sundisol uppgår till 17,0 MSEK på skuldfri basis vilket beräknas motsvara en multipel om 4,1x EV/EBITDA, varav 15 MSEK erläggs kontant och 2 MSEK genom revers med 3 års löptid och
Styrelsen i HMS Networks AB (publ) har beslutat att utnyttja bemyndigande om återköp av aktier22.10.2021 14:42:18 CEST | Pressemelding
Styrelsen i HMS Networks AB (publ) ("HMS") har med stöd av bemyndigandet från årsstämman den 23 april 2021 fattat beslut om förvärv av egna aktier på Nasdaq Stockholm. Förvärv av egna aktier ska genomföras inom ramen för ett återköpsprogram vilket syftar till att säkerställa HMS åtaganden att leverera prestationsaktier enligt HMS Aktiesparprogram 2022-2025. Återköpen får inledas den 25 oktober 2021 och kommer att ske vid ett eller flera tillfällen intill årsstämman 2022. Återköpen kommer att ske på Nasdaq Stockholm i enlighet med Nordic Main Market Rulebook for Issuers of Shares och förvaltas av Skandinaviska Enskilda Banken AB (publ) som fattar handelsbeslut vad avser de tidpunkter då återköpen sker oberoende av HMS. Återköp kommer ske till ett pris per aktie inom det vid var tid registrerade kursintervallet, varmed avses intervallet mellan högsta köpkurs och lägsta säljkurs. Återköp får ske av högst 81 000 aktier. Betalning av aktierna kommer att erläggas kontant. Rapportering kommer